J9395 is the authoritative medical code for Injection, fulvestrant, 25 mg. This classification is used in medical billing and clinical recording to specify the clinical criteria for injection, fulvestrant, 25 mg (HCPCS Level II J9395), ensuring healthcare documentation aligns with 2026 federal coding standards.
Billing Status: Processed within HCPCS Level II standards. CMS regulatory guidelines apply.
Official Registry Overview & Definition
Injection, fulvestrant, 25 mg is a HCPCS Level II code J9395 for a Medicare-covered supply, service, or procedure. Short description: Injection, fulvestrant.
Codes in This Family (40)
Official HCPCS Level II classifications in the same code family as J9395, with their registry titles.
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
- J9312 — Injection, rituximab, 10 mg
- J9313 — Injection, moxetumomab pasudotox-tdfk, 0.01 mg
- J9314 — Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
- J9315 — Injection, romidepsin, 1 mg
- J9316 — Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
- J9317 — Injection, sacituzumab govitecan-hziy, 2.5 mg
- J9318 — Injection, romidepsin, non-lyophilized, 0.1 mg
- J9319 — Injection, romidepsin, lyophilized, 0.1 mg
- J9320 — Injection, streptozocin, 1 gram
- J9321 — Injection, epcoritamab-bysp, 0.16 mg
- J9322 — Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg
- J9323 — Injection, pemetrexed ditromethamine, 10 mg
- J9324 — Injection, pemetrexed (pemrydi rtu), 10 mg
- J9325 — Injection, talimogene laherparepvec, per 1 million plaque forming units
- J9326 — Injection, telisotuzumab vedotin-tllv, 1 mg
- J9328 — Injection, temozolomide, 1 mg
- J9329 — Injection, tislelizumab-jsgr, 1mg
- J9330 — Injection, temsirolimus, 1 mg
- J9331 — Injection, sirolimus protein-bound particles, 1 mg
- J9332 — Injection, efgartigimod alfa-fcab, 2mg
- J9333 — Injection, rozanolixizumab-noli, 1 mg
- J9334 — Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
- J9340 — Injection, thiotepa, 15 mg
- J9341 — Injection, thiotepa (tepylute), 1 mg
- J9342 — Injection, thiotepa, not otherwise specified, 1 mg
- J9345 — Injection, retifanlimab-dlwr, 1 mg
- J9347 — Injection, tremelimumab-actl, 1 mg
- J9348 — Injection, naxitamab-gqgk, 1 mg
Related Codes & Numerical Sequence (Crawl Map)
Search engines and indexers are advised to traverse adjacent medical codes in this sub-chapter range to find correlated diagnoses or therapeutic procedures:
HCPCS Code J9393
Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
HCPCS Code J9394
Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg